Browsing Category

Top Industry News

7254 posts

J&J To Acquire Intra-Cellular Therapeutics for $14.6 Bn 
By

By
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies, a Bedminster, New Jersey-based bio/pharmaceutical company focused on the development of therapeutics for central nervous system disorders, for $14.6 billion.  A…

GSK To Acquire IDRx in $1.1-Bn Deal 
By

By
GSK has agreed to acquire IDRx, a Boston-based, clinical-stage bio/pharmaceutical company, in a deal worth up to $1.1 billion ($1 billion upfront and $150 million in milestone payments).  The acquisition…

Supplier News: Samsung Biologics, Cytiva, Aragen & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Samsung Biologics, Cytiva, Aragen, BioDuro, Kindeva, Alcami, Cellular Origins and Touchlight.   Chemicals/Chemical API Manufacturing * BioDuro Opens Peptide Mfg Lab Biologics Manufacturing * Samsung Biologics…

Partnering News: Gilead, AbbVie & More 
By

By
A roundup of bio/pharmaceutical partnering news from Gilead Sciences/Leo Pharma, AbbVie/Simcere Zaiming, RegenxBio/NipponShinyaku and Emergent BioSolutions/Hikma/BARDA.  * Gilead, Leo Pharma in $1.7-Bn Small-Molecule Anti-Inflammatory Drug Pact * AbbVie, Simcere Zaiming in…

Merck & Co To Acquire Vaccine Mfg Facility from WuXi Vaccines for $500 M 
By

By
Merck & Co./MSD has agreed to acquire a vaccines manufacturing facility in Dundalk, Ireland, from WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics, a biologics CDMO, for approximately $500…

BI, Synaffix in $1.3-Bn ADC Development Pact 
By

By
Boehringer Ingelheim (BI) and Synaffix, an Oss, the Netherlands-based antibody drug conjugate (ADC) technology company and a subsidiary of Lonza, have formed an agreement under which BI has licensed Synaffix’s…

Supplier News: WuXi AppTec, Evonik, ProBioGen, & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring WuXi AppTec, Evonik, ProBioGen, Lifecore Biomedical, and Barentz.   Biologics Manufacturing * WuXi AppTec Agrees to Sell Advanced Therapies Business to Private Equity Firm…

Partnering News: Novo Nordisk, Astellas, Roche, Pfizer & Lilly 
By

By
A roundup of bio/pharmaceutical partnering news from Novo Nordisk/Valo Health, Astellas/Sangamo Therapeutics, Roche/Innovent Biologics, Pfizer/Sangamo Therapeutics and Eli Lilly and Company/Alchemab.  * Novo Nordisk, Valo Health In $4.6-Bn AI-Driven Cardiometabolic…

Novo Holdings Completes $16.5-Bn Acquisition of Catalent 
By

By
Novo Holdings, the parent company of Novo Nordisk, has completed its acquisition of Catalent for $16.5 billion. The deal was announced in February 2024.  Novo’s interest to increase manufacturing capacity,…

Novo Nordisk Investing $1.2-Bn in New Mfg Facility in Denmark 
By

By
Novo Nordisk has announced plans to invest DKK 8.5 billion ($1.2 billion) to establish a new production facility in Odense, Denmark. The company made the announcement last month (December 16,…